MX2024012532A - Composiciones de oligonucleótidos y métodos relacionados con las mismas - Google Patents
Composiciones de oligonucleótidos y métodos relacionados con las mismasInfo
- Publication number
- MX2024012532A MX2024012532A MX2024012532A MX2024012532A MX2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A MX 2024012532 A MX2024012532 A MX 2024012532A
- Authority
- MX
- Mexico
- Prior art keywords
- present disclosure
- oligonucleotide compositions
- methods related
- oligonucleotides
- modifications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331756P | 2022-04-15 | 2022-04-15 | |
| US202263397320P | 2022-08-11 | 2022-08-11 | |
| US202263411062P | 2022-09-28 | 2022-09-28 | |
| US202363454299P | 2023-03-23 | 2023-03-23 | |
| PCT/US2023/018742 WO2023201095A2 (en) | 2022-04-15 | 2023-04-14 | Oligonucleotide compositions and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012532A true MX2024012532A (es) | 2024-12-06 |
Family
ID=88330318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012532A MX2024012532A (es) | 2022-04-15 | 2024-10-09 | Composiciones de oligonucleótidos y métodos relacionados con las mismas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250262235A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4507700A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513847A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250004787A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119317632A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023253657A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247824A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316178A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012532A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023201095A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| EP4784753A2 (en) | 2023-09-27 | 2026-08-05 | Judo Bio Inc. | Slc6a19-targeting modulatory nucleic acid agents |
| AU2024348221A1 (en) | 2023-09-27 | 2026-04-30 | Judo Bio Inc. | Aminoglycosides for delivery of agents to the kidney |
| EP4784172A1 (en) | 2023-09-27 | 2026-08-05 | Judo Bio Inc. | Polymyxins for delivery of agents to the kidney |
| CN117866028A (zh) * | 2024-01-05 | 2024-04-12 | 苏州诺维康生物科技有限公司 | 一种医药中间体及其制备方法 |
| WO2025213136A1 (en) * | 2024-04-05 | 2025-10-09 | Wave Life Sciences Ltd. | Oligonucleotides comprising pn linkages and methods thereof |
| WO2026050243A1 (en) * | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026096688A1 (en) * | 2024-10-30 | 2026-05-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
-
2023
- 2023-04-14 EP EP23789042.1A patent/EP4507700A2/en active Pending
- 2023-04-14 CA CA3247824A patent/CA3247824A1/en active Pending
- 2023-04-14 IL IL316178A patent/IL316178A/en unknown
- 2023-04-14 CN CN202380044985.5A patent/CN119317632A/zh active Pending
- 2023-04-14 WO PCT/US2023/018742 patent/WO2023201095A2/en not_active Ceased
- 2023-04-14 KR KR1020247037794A patent/KR20250004787A/ko active Pending
- 2023-04-14 JP JP2024560379A patent/JP2025513847A/ja active Pending
- 2023-04-14 US US18/856,553 patent/US20250262235A1/en active Pending
- 2023-04-14 AU AU2023253657A patent/AU2023253657A1/en active Pending
-
2024
- 2024-10-09 MX MX2024012532A patent/MX2024012532A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023253657A1 (en) | 2024-11-14 |
| KR20250004787A (ko) | 2025-01-08 |
| JP2025513847A (ja) | 2025-04-30 |
| IL316178A (en) | 2024-12-01 |
| WO2023201095A2 (en) | 2023-10-19 |
| CN119317632A (zh) | 2025-01-14 |
| US20250262235A1 (en) | 2025-08-21 |
| WO2023201095A3 (en) | 2023-12-07 |
| CA3247824A1 (en) | 2023-10-19 |
| EP4507700A2 (en) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023201095A3 (en) | Oligonucleotide compositions and methods relating thereto | |
| AR112779A1 (es) | Composiciones de nucleótidos y métodos relacionados | |
| CA3179051A1 (en) | Double stranded oligonucleotide compositions and methods relating thereto | |
| MX2021012862A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| MX2023005326A (es) | Composiciones de oligonucleótidos y métodos de las mismas. | |
| MX2023015523A (es) | Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos. | |
| CL2022002711A1 (es) | Conjugados de anticuerpo-fármaco que comprenden agonistas de sting | |
| CL2020002401A1 (es) | Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas. | |
| CO2024005352A2 (es) | Composiciones de oligonucleótidos y métodos de estas | |
| CO2018008196A2 (es) | Dinucleótidos cíclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferón (sting) tales como cáncer | |
| MX2018016253A (es) | Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos. | |
| DOP2024000081A (es) | Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos | |
| AR106135A1 (es) | Moduladores de la expresión del sarcoma de la rata de kirsten (kras) | |
| MX2022002532A (es) | Métodos para generar y aislar neuronas de dopamina del mesencéfalo. | |
| ECSP066268A (es) | Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares | |
| GT200500221A (es) | Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan. | |
| MX2022001767A (es) | Construcciones de vesículas-oligonucleótidos antisentido (aso) extracelulares que se dirigen a transductor de señal y activador de la transcripción 6 (stat6). | |
| DOP2024000225A (es) | Composiciones y métodos para inhibir la expresión de mapt | |
| CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| CL2022000262A1 (es) | Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251) | |
| CL2025003326A1 (es) | Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| Robalo et al. | Other-regarding preferences, in-group bias and political participation: An experiment | |
| WO2023091644A3 (en) | Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto | |
| AR122534A1 (es) | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |